Citrullination of linear and cyclic altered peptide ligands from myelin basic protein (MBP87-99) epitope elicits a Th1 polarized response by T cells isolated from multiple sclerosis patients: Implications in triggering disease

Journal of Medicinal Chemistry

Volumn 51, Issue 24, 2008, Pages 7834-7842

  Deraos, George ^a   Chatzantoni, Kokona ^b   Matsoukas, Minos Timotheos ^a   Tselios, Theodore ^a   Deraos, Spyros ^a   Katsara, Maria ^a,c   Papathanasopoulos, Panagiotis ^b   Vynios, Demitrios ^a   Apostolopoulos, Vasso ^c   Mouzaki, Athanasia ^b   Matsoukas, John ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c BURNET INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CITRULLINE; EPITOPE; MYELIN BASIC PROTEIN; MYELIN BASIC PROTEIN CYCLO[87-99][91 CITRULLINE 96 ALANINE 97 CITRULLINE]; MYELIN BASIC PROTEIN[87-99][91 CITRULLINE 96 ALANINE 97 CITRULLINE]; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELLULAR IMMUNITY; CHEMICAL REACTION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE PREDISPOSITION; DRUG DESIGN; DRUG SYNTHESIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MALE; MASS SPECTROMETRY; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; POLARIZATION; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE; TH1 CELL; THIN LAYER CHROMATOGRAPHY;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; CITRULLINE; DRUG DESIGN; EPITOPES; HUMANS; LEUKOCYTES, MONONUCLEAR; LIGANDS; MODELS, CHEMICAL; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; PEPTIDES; PEPTIDES, CYCLIC; TH1 CELLS;

EID: 58149088749     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800891n     Document Type: Article

References (56)

1. Katsara, M.; Matsoukas, J.; Deraos, G.; Apostolopoulos, V. Towards immunotherapeutic drugs and vaccines against multiple sclerosis. Acta Biochim Biophys Sin. 2008, 40, 636-642.
2. Holmoy, T.; Hestvik, A. L. Multiple sclerosis: immunopathogenesis and controversies in defining the cause. Curr. Opin. Infect. Dis. 2008, 21, 271-278.
3. Polman, C. H.; Uitdehaag, B. M. New and emerging treatment options for multiple sclerosis. Lancet Neurol. 2003, 2, 563-566.
4. Steinman, L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 1996, 85, 299-302.
5. Evavold, B. D.; Sloan-Lancaster, J.; Allen, P. M. Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands. Immunol. Today 1993, 14, 602-609.
6. Evavold, B. D.; Allen, P. M. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science 1991, 252, 1308-1310.
7. Hedegaard, C. J.; Krakauer, M.; Bendtzen, K.; Lund, H.; Sellebjerg, F.; Nielsen, C. H. T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology 2008, 125, 161-169.
8. Katsara, M.; Deraos, G.; Tselios, T.; Matsoukas, J.; Apostolopoulos, V. Design of novel cyclic altered peptide ligands of myelin basic protein MBP83-99 that modulate immune responses in SJL/J mice. J. Med. Chem. 2008, 51, 3971-3978.
9. Katsara, M.; Yuriev, E.; Ramsland, P. A.; Deraos, G.; Tselios, T.; Matsoukas, J.; Apostolopoulos, V. A double mutation of MBP(83-99) peptide induces IL-4 responses and antagonizes IFN-gamma responses. J. Neuroimmunol. 2008, 200, 77-89.
10. Katsara, M.; Yuriev, E.; Ramsland, P. A.; Deraos, G.; Tselios, T.; Matsoukas, J.; Apostolopoulos, V. Mannosylation of mutated MBP83-99 peptides diverts immune responses from Th1 to Th2. Mol. Immunol. 2008, 45, 3661-3670.
11. Mouzaki, A.; Tselios, T.; Papathanassopoulos, P.; Matsoukas, I.; Chatzantoni, K. Immunotherapy for multiple sclerosis: basic insights for new clinical strategies. Curr. Neurovasc. Res. 2004, 1, 325-340.
12. Degano, M.; Garcia, K. C.; Apostolopoulos, V.; Rudolph, M. G.; Teyton, L.; Wilson, I. A. A functional hot spot for antigen recognition in a superagonist TCR/MHC complex. Immunity 2000, 12, 251-261.
13. Kalergis, A. M.; Nathenson, S. G. Altered peptide ligand-mediated TCR antagonism can be modulated by a change in a single amino acid residue within the CDR3 beta of an MHC class I-restricted TCR. J. Immunol. 2000, 165, 280-285.
14. Thomson, C. T.; Kalergis, A. M.; Sacchettini, J. C.; Nathenson, S. G. A structural difference limited to one residue of the antigenic peptide can profoundly alter the biological outcome of the TCR-peptide/MHC class I interaction. J. Immunol. 2001, 166, 3994-3997.
15. Bielekova, B.; Goodwin, B.; Richert, N.; Cortese, I.; Kondo, T.; Afshar, G.; Gran, B.; Eaton, J.; Antel, J.; Frank, J. A.; McFarland, H. F.; Martin, R. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 2000, 6, 1167-1175.
16. Crowe, P. D.; Qin, Y.; Conlon, P. J.; Antel, J. P. NBI-5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients. Ann. Neurol. 2000, 48, 758-765.
17. Kappos, L.; Comi, G.; Panitch, H.; Oger, J.; Antel, J.; Conlon, P.; Steinman, L. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat. Med. 2000, 6, 1176-1182.
18. Kim, H. J.; Antel, J. P.; Duquette, P.; Alleva, D. G.; Conlon, P. J.; Bar-Or, A. Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand. Clin. Immunol. 2002, 104, 105-114.
19. Tselios, T.; Daliani, I.; Deraos, S.; Thymianou, S.; Matsoukas, E.; Troganis, A.; Gerothanassis, I.; Mouzaki, A.; Mavromoustakos, T.; Probert, L.; Matsoukas, J. Treatment of experimental allergic encephalomyelitis (EAE) by a rationally designed cyclic analogue of myelin basic protein (MBP) epitope 72-85. Bioorg. Med. Chem. Lett. 2000, 10, 2713-2717.
20. Tselios, T.; Probert, L.; Daliani, I.; Matsoukas, E.; Troganis, A.; Gerothanassis, I. P.; Mavromoustakos, T.; Moore, G. J.; Matsoukas, J. M. Design and synthesis of a potent cyclic analogue of the myelin basic protein epitope MBP72-85: importance of the Ala81 carboxyl group and of a cyclic conformation for induction of experimental allergic encephalomyelitis. J. Med. Chem. 1999, 42, 1170-1177.
21. Tselios, T.; Apostolopoulos, V.; Daliani, I.; Deraos, S.; Grdadolnik, S.; Mavromoustakos, T.; Melachrinou, M.; Thymianou, S.; Probert, L.; Mouzaki, A.; Matsoukas, J. Antagonistic effects of human cyclic MBP(87-99) altered peptide ligands in experimental allergic encephalomyelitis and human T-cell proliferation. J. Med. Chem. 2002, 45, 275-283.
22. Tselios, T.; Daliani, I.; Probert, L.; Deraos, S.; Matsoukas, E.; Roy, S.; Pires, J.; Moore, G.; Matsoukas, J. Treatment of experimental allergic encephalomyelitis (EAE) induced by guinea pig myelin basic protein epitope 72-85 with a human MBP(87-99) analogue and effects of cyclic peptides. Bioorg. Med. Chem. 2000, 8, 1903-1909.
23. Matsoukas, J.; Apostolopoulos, V.; Kalbacher, H.; Papini, A. M.; Tselios, T.; Chatzantoni, K.; Biagioli, T.; Lolli, F.; Deraos, S.; Papathanassopoulos, P.; Troganis, A.; Mantzourani, E.; Mavromoustakos, T.; Mouzaki, A. Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators. J. Med. Chem. 2005, 48, 1470-1480.
24. Matsuo, K.; Xiang, Y.; Nakamura, H.; Masuko, K.; Yudoh, K.; Noyori, K.; Nishioka, K.; Saito, T.; Kato, T. Identification of novel citrullinated autoantigens of synovium in rheumatoid arthritis using a proteomic approach. Arthritis Res. Ther. 2006, 8, R175.
25. Pritzker, L. B.; Joshi, S.; Gowan, J. J.; Harauz, G.; Moscarello, M. A. Deimination of myelin basic protein. 1. Effect of deimination of arginyl residues of myelin basic protein on its structure and susceptibility to digestion by cathepsin D. Biochemistry 2000, 39, 5374-5381.
26. Pritzker, L. B.; Joshi, S.; Harauz, G.; Moscarello, M. A. Deimination of myelin basic protein. 2. Effect of methylation of MBP on its deimination by peptidylarginine deiminase. Biochemistry 2000, 39, 5382-5388.
27. Tranquill, L. R.; Cao, L.; Ling, N. C.; Kalbacher, H.; Martin, R. M.; Whitaker, J. N. Enhanced T cell responsiveness to citrulline-containing myelin basic protein in multiple sclerosis patients. Mult. Scler. 2000, 6, 220-225.
28. Martin, R.; Whitaker, J. N.; Rhame, L.; Goodin, R. R.; McFarland, H. F. Citrulline-containing myelin basic protein is recognized by T-cell lines derived from multiple sclerosis patients and healthy individuals. Neurology 1994, 44, 123-129.
29. Gauthier, L.; Smith, K. J.; Pyrdol, J.; Kalandadze, A.; Strominger, J. L.; Wiley, D. C.; Wucherpfennig, K. W. Expression and crystallization of the complex of HLA-DR2 (DRA, DRB1*1501) and an immunodominant peptide of human myelin basic protein. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 11828-11833.
30. Smith, K. J.; Pyrdol, J.; Gauthier, L.; Wiley, D. C.; Wucherpfennig, K. W. Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. J. Exp. Med. 1998, 188, 1511-1520.
31. Wucherpfennig, K. W.; Hafler, D. A.; Strominger, J. L. Structure of human T-cell receptors specific for an immunodominant myelin basic protein peptide: positioning of T-cell receptors on HLA-DR2/peptide complexes. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 8896-8900.
32. Hahn, M.; Nicholson, M. J.; Pyrdol, J.; Wucherpfennig, K. W. Unconventional topology of self peptide-major histocompatibility complex binding by a human autoimmune T cell receptor. Nat. Immunol. 2005, 6, 490-496.
33. Fearon, W. R. The carbamido diacetyl reaction: a test for citrulline. Biochem. J. 1939, 33, 902-907.
34. Boggs, J. M.; Rangaraj, G.; Koshy, K. M.; Ackerley, C.; Wood, D. D.; Moscarello, M. A. Highly deiminated isoform of myelin basic protein from multiple sclerosis brain causes fragmentation of lipid vesicles. J. Neurosci. Res. 1999, 57, 529-535.
35. Gyorgy, B.; Toth, E.; Tarcsa, E.; Falus, A.; Buzas, E. I. Citrullination: a posttranslational modification in health and disease. Int. J. Biochem. Cell Biol. 2006, 38, 1662-1677.
36. Girelli, F.; Foschi, F. G.; Bedeschi, E.; Calderoni, V.; Stefanini, G. F.; Martinelli, M. G. Is anti cyclic citrullinated peptide a useful laboratory test for the diagnosis of rheumatoid arthritis? Eur. Ann. Allergy Clin. Immunol. 2004, 36, 127-130.
37. Lee, A. N.; Beck, C. E.; Hall, M. Rheumatoid factor and anti-CCP autoantibodies in rheumatoid arthritis: a review. Clin. Lab. Sci. 2008, 21, 15-18.
38. Ireland, J.; Herzog, J.; Unanue, E. R. Cutting edge: unique T cells that recognize citrullinated peptides are a feature of protein immunization. J. Immunol. 2006, 177, 1421-1425.
39. Hill, J. A.; Southwood, S.; Sette, A.; Jevnikar, A. M.; Bell, D. A.; Cairns, E. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J. Immunol. 2003, 171, 538-541.
40. Moscarello, M. A.; Mastronardi, F. G.; Wood, D. D. The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochem. Res. 2007, 32, 251-256.
41. Cao, L.; Sun, D.; Whitaker, J. N. Citrullinated myelin basic protein induces experimental autoimmune encephalomyelitis in Lewis rats through a diverse T cell repertoire. J. Neuroimmunol. 1998, 88, 21-29.
42. Kim, J. K.; Mastronardi, F. G.; Wood, D. D.; Lubman, D. M.; Zand, R.; Moscarello, M. A. Multiple sclerosis: an important role for post-translational modifications of myelin basic protein in pathogenesis. Mol. Cell. Proteomics 2003, 2, 453-462.
43. Harauz, G.; Musse, A. A. A tale of two citrullines - structural and functional aspects of myelin basic protein deimination in health and disease. Neurochem. Res. 2007, 32, 137-158.
44. Wood, D. D.; Moscarello, M. A. The isolation, characterization, and lipid-aggregating properties of a citrulline containing myelin basic protein. J. Biol. Chem. 1989, 264, 5121-5127.
45. Raijmakers, R.; Vogelzangs, J.; Croxford, J. L.; Wesseling, P.; van Venrooij, W. J.; Pruijn, G. J. Citrullination of central nervous system proteins during the development of experimental autoimmune encephalomyelitis. J. Comp. Neurol. 2005, 486, 243-253.
46. Correale, J.; Gilmore, W.; McMillan, M.; Li, S.; McCarthy, K.; Le, T.; Weiner, L. P. Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J. Immunol. 1995, 154, 2959-2968.
47. Wraith, D. C. Role of interleukin-10 in the induction and function of natural and antigen-induced regulatory T cells. J. Autoimmun. 2003, 20, 273-275.
48. Scalzo, K.; Plebanski, M.; Apostolopoulos, V. Regulatory T-cells: immunomodulators in health and disease. Curr. Top. Med. Chem. 2006, 6, 1759-1768.
49. Spyranti, Z.; Dalkas, G. A.; Spyroulias, G. A.; Mantzourani, E. D.; Mavromoustakos, T.; Friligou, I.; Matsoukas, J. M.; Tselios, T. V. Putative bioactive conformations of amide linked cyclic myelin basic protein peptide analogues associated with experimental autoimmune encephalomyelitis. J. Med. Chem. 2007, 50, 6039-6047.
50. Mantzourani, E. D.; Tselios, T. V.; Grdadolnik, S. G.; Brancale, A.; Platts, J. A.; Matsoukas, J. M.; Mavromoustakos, T. M. A putative bioactive conformation for the altered peptide ligand of myelin basic protein and inhibitor of experimental autoimmune encephalomyelitis [Arg91, Ala96] MBP87-99. J. Mol. Graphics Modell. 2006, 25, 17-29.
51. Mantzourani, E. D.; Platts, J. A.; Brancale, A.; Mavromoustakos, T. M.; Tselios, T. V. Molecular dynamics at the receptor level of immunodominant myelin basic protein epitope 87-99 implicated in multiple sclerosis and its antagonists altered peptide ligands: triggering of immune response. J. Mol. Graphics Modell. 2007, 26, 471-481.
52. Mantzourani, E. D.; Tselios, T. V.; Grdadolnik, S. G.; Platts, J. A.; Brancale, A.; Deraos, G. N.; Matsoukas, J. M.; Mavromoustakos, T. M. Comparison of proposed putative active conformations of myelin basic protein epitope 87-99 linear altered peptide ligands by spectroscopic and modelling studies: the role of positions 91 and 96 in T-cell receptor activation. J. Med. Chem. 2006, 49, 6683-6691.
53. Rothnagel, J. A.; Rogers, G. E. Citrulline in proteins from the enzymatic deimination of arginine residues. Methods Enzymol. 1984, 107, 624-631.
54. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 1983, 4, 187-217.
55. Chen, J.; Im, W.; Brooks, C. L. Balancing solvation and intramolecular interactions: toward a consistent generalized Born force field. J. Am. Chem. Soc. 2006, 128, 3728-3736.
56. Ryckaert, J.-P.; Ciccotti, G.; Berendsen, H. J. C. Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 1977, 23, 327-341.